An irregular heartbeat that arrives without warning, a racing pulse at rest, moments of breathlessness that seem to come from nowhere. For many people, these are the first signs that something is happening with the heart's electrical system. For a large proportion of them, the cause is atrial fibrillation.
Atrial fibrillation is the most common sustained cardiac arrhythmia worldwide. It affects an estimated 59 million people globally and its prevalence is rising steadily in India alongside the increasing rates of hypertension, diabetes, and obesity that are AFib's most significant risk drivers. Many people in India live with AFib undiagnosed for years, either because symptoms are attributed to other causes or because the condition is not yet producing symptoms they recognise.
Understanding what AFib is, why it matters, and what atrial fibrillation treatment in Chennai now offers is the first step toward managing the condition effectively.
What Is Atrial Fibrillation?
The heart has four chambers. The two upper chambers are the atria. In a normal heartbeat, an electrical signal fires from the sinoatrial node in the right atrium, spreads through the atria causing them to contract together, and then passes through the atrioventricular node to the ventricles below.
In atrial fibrillation, the atria receive chaotic, disorganised electrical signals from multiple sites simultaneously. Instead of contracting in a coordinated, organised way, the atrial walls quiver irregularly. This quivering is the fibrillation. The ventricular response is also irregular because the atrioventricular node receives these chaotic signals at unpredictable intervals, producing the characteristic irregular pulse that a doctor or patient can feel.
AFib is classified by its pattern:
| Type | Definition |
|---|---|
| Paroxysmal | Episodes that start and stop on their own within 7 days |
| Persistent | Episodes lasting more than 7 days, requiring treatment to restore normal rhythm |
| Long-standing persistent | Continuous AFib lasting more than 12 months |
| Permanent | AFib where the decision is made not to attempt rhythm restoration, focusing on rate control and stroke prevention |
Symptoms of Atrial Fibrillation
AFib produces a wide range of symptom experiences. Some patients are highly symptomatic and notice every episode. Others have AFib diagnosed incidentally on a routine ECG with no symptoms at all.
Common symptoms of AFib include:
-
Palpitations: a sensation of the heart fluttering, racing, or beating irregularly
-
Breathlessness on exertion or at rest, disproportionate to the level of activity
-
Fatigue and a sense of reduced exercise tolerance that has developed gradually
-
Dizziness or lightheadedness
-
Chest discomfort or a sense of pressure, particularly during faster ventricular rates
-
Reduced ability to exercise that the person may have attributed to ageing or unfitness
The key clinical point is that the absence of symptoms does not mean the absence of risk. Asymptomatic AFib carries the same stroke risk as symptomatic AFib. Stroke risk is determined by the underlying condition and comorbidities, not by whether the patient feels the arrhythmia.
Why Atrial Fibrillation Needs to Be Treated
Stroke Risk
Stroke is the most serious consequence of untreated atrial fibrillation. In AFib, the atria do not contract properly, and blood can pool and clot in a small pouch in the left atrium called the left atrial appendage. If a clot dislodges, it travels to the brain and causes an embolic stroke. AFib-related strokes are on average larger and more disabling than strokes from other causes.
The 2024 ESC Guidelines use the CHA2-VA scoring system to quantify stroke risk in AFib patients. The score includes congestive heart failure, hypertension, age above 65 (score 1) and above 75 (score 2), diabetes mellitus, prior stroke or transient ischaemic attack (score 2), and vascular disease. Anticoagulation is recommended at a CHA2-VA score of 2 or above and should be considered at a score of 1.
Heart Failure
A rapid and persistently irregular ventricular rate in uncontrolled AFib causes the heart muscle to work harder than it should for sustained periods. Over months to years, this can weaken the heart muscle and lead to tachycardia-induced cardiomyopathy, a form of heart failure that is partially or fully reversible with adequate rate control or rhythm restoration.
Quality of Life and Function
Even when stroke and heart failure risk is managed, AFib symptoms themselves significantly impair quality of life in many patients. Fatigue, exercise intolerance, palpitations, and breathlessness restrict daily activity, work capacity, and participation in physical activity. Reducing these symptoms is a central goal of modern AFib treatment.
The 2024 ESC AF-CARE Pathway: A Modern Framework for AFib Treatment
The 2024 ESC Guidelines for the Management of Atrial Fibrillation introduced the AF-CARE pathway as the organising framework for treatment. AF-CARE stands for:
C - Comorbidities and risk factors: Manage the conditions that drive AFib and worsen it. Hypertension, diabetes, obesity, heart failure, sleep apnoea, physical inactivity, and heavy alcohol use are all modifiable contributors to AFib burden. The 2024 guidelines specifically recommend SGLT2 inhibitors for patients with both heart failure and AFib regardless of ejection fraction, weight loss targeting at least 10% body weight reduction in overweight patients, alcohol limitation to no more than 3 standard drinks per week, and 150 to 300 minutes of moderate aerobic activity weekly.
A - Avoid stroke and thromboembolism: Anticoagulation is the cornerstone. DOACs (direct oral anticoagulants, including rivaroxaban, apixaban, dabigatran, and edoxaban) are preferred over vitamin K antagonists (warfarin) in eligible patients because of their more predictable effect, fewer drug and food interactions, and lower bleeding risk. Antiplatelet agents alone (aspirin) are not recommended for stroke prevention in AFib and should not be substituted for anticoagulation.
R - Reduce symptoms with rate and rhythm control: Using medications, cardioversion, and ablation procedures to control the ventricular rate and restore normal rhythm where possible.
E - Evaluate and reassess: Periodic review to identify new modifiable risk factors, assess treatment response, and adjust strategy as the condition and the patient's circumstances evolve.
Rate Control: Slowing the Irregular Heartbeat
Rate control is the treatment strategy of reducing the ventricular rate (the speed at which the lower chambers respond to atrial signals), without attempting to restore the regular, coordinated atrial rhythm.
The target ventricular rate is generally a resting heart rate below 110 beats per minute as a starting target, with tighter control considered in patients with ongoing symptoms.
Rate control medications used in atrial fibrillation treatment in Chennai and T Nagar include:
-
Beta-blockers (bisoprolol, metoprolol, carvedilol): first-line rate control agents suitable for patients at any ejection fraction. They reduce ventricular response rate and are safe in heart failure with reduced ejection fraction.
-
Digoxin: suitable at any ejection fraction, particularly useful in sedentary patients and as an add-on agent when beta-blockers alone are insufficient.
-
Non-dihydropyridine calcium channel blockers (diltiazem, verapamil): effective rate control agents but used only in patients with left ventricular ejection fraction above 40%, as they are contraindicated in heart failure with reduced ejection fraction.
Rate control alone does not restore a regular heartbeat. It reduces the risk of tachycardia-induced cardiomyopathy and reduces symptoms related to a fast ventricular rate, but the underlying irregularity of the atrial rhythm remains.


Rhythm Control: Restoring the Regular Heartbeat
Rhythm control aims to restore and maintain normal sinus rhythm, bringing the atria back into coordinated, organised electrical activity. The 2024 ESC guidelines recommend considering rhythm control for all suitable AFib patients, with the primary goal of reducing symptoms and improving quality of life.
Antiarrhythmic Drug Therapy
Antiarrhythmic drugs suppress the abnormal electrical signals that initiate and sustain AFib. Commonly used agents include:
-
Flecainide and propafenone: suitable for patients with paroxysmal AFib and no structural heart disease. May be used as pill-in-the-pocket therapy for episodic AFib in selected patients.
-
Amiodarone: effective across a broad range of patients including those with structural heart disease and heart failure, but associated with thyroid, pulmonary, and hepatic side effects with long-term use, requiring monitoring.
-
Sotalol: combined rate-slowing and antiarrhythmic action, used in selected patients.
-
Dronedarone: used for non-permanent AFib in patients without severe heart failure, with a safer side effect profile than amiodarone.
Cardioversion
Cardioversion is the procedure to restore normal sinus rhythm when the patient is in ongoing AF.
Electrical cardioversion (DCCV): A synchronised electric shock delivered under brief sedation resets the heart's electrical activity to sinus rhythm. It is effective in the short term but the rate of AF recurrence within twelve months is significant without ongoing antiarrhythmic therapy or ablation.
Pharmacological cardioversion: Intravenous antiarrhythmic agents (flecainide, amiodarone) convert AF to sinus rhythm in selected patients. Less reliable than electrical cardioversion for persistent AF.
Anticoagulation is required before cardioversion in patients who have been in AF for more than 48 hours or whose duration is unknown, to reduce the risk of stroke from dislodgement of atrial thrombus during cardioversion.
Catheter Ablation
Catheter ablation is the most effective rhythm control option for appropriate candidates and has become a central pillar of atrial fibrillation treatment in T Nagar and Chennai for patients seeking long-term rhythm control.
The standard ablation procedure is pulmonary vein isolation (PVI). The pulmonary veins, which drain into the left atrium, are the most common origin of the ectopic triggers that initiate paroxysmal AFib. Ablation creates a line of electrical block around the openings of the pulmonary veins in the left atrium, preventing these triggers from initiating AF. This is performed percutaneously via catheters passed through the femoral vein and across the atrial septum.
The 2024 ESC guidelines recommend:
-
Catheter ablation as first-line rhythm control for paroxysmal AFib in appropriate candidates
-
Catheter ablation after antiarrhythmic drug failure for persistent AFib
-
Repeat ablation if AF recurs after an initial procedure that improved symptoms
Anticoagulation must be continued for at least two months after ablation regardless of stroke risk score, because ablation does not immediately eliminate the stroke risk associated with AF.
Surgical and Hybrid Options
For patients in whom catheter ablation has failed or who are undergoing cardiac surgery for other reasons, surgical options are available. The 2024 ESC guidelines recommend:
-
Endoscopic or hybrid ablation (combining catheter and surgical approaches) when catheter ablation has failed, or as an alternative in persistent AF refractory to antiarrhythmic drugs
-
AF ablation during cardiac surgery (particularly mitral valve surgery) at experienced centres
-
Left atrial appendage closure (LAAC) as an adjunct to anticoagulation in patients at high stroke risk and high bleeding risk
Managing Lifestyle Risk Factors for AFib in Chennai
The 2024 ESC AF-CARE guidelines place unusual emphasis on lifestyle and risk factor modification as active treatment for AFib, not merely background advice. This is particularly relevant for patients seeking atrial fibrillation treatment in Chennai, where hypertension, diabetes, and obesity rates in urban adults create a high-risk background for AFib development and progression.
Key modifiable risk factors and the evidence-based targets:
-
Hypertension: The single most common and modifiable risk factor for AFib. Sustained BP control reduces both AFib incidence and stroke risk. Target BP below 130/80 mmHg.
-
Obesity: Weight loss of at least 10% of body weight in overweight patients with AFib is specifically recommended in the 2024 ESC guidelines for reducing AF burden and improving quality of life.
-
Sleep apnoea: Untreated obstructive sleep apnoea dramatically increases AFib recurrence after ablation. Screening and CPAP treatment reduce AF burden.
-
Alcohol: Even moderate alcohol consumption increases AF burden. The 2024 ESC guidelines recommend limiting alcohol to 3 or fewer standard drinks per week.
-
Physical inactivity: 150 to 300 minutes of moderate aerobic activity weekly reduces AF burden. However, extreme endurance exercise (marathon running, long-distance cycling) is paradoxically associated with increased AF risk in long-term competitive athletes.
-
Diabetes: Good glycaemic control reduces AF progression. SGLT2 inhibitors, in addition to glycaemic benefits, have specific cardiac benefits for AFib patients with coexisting heart failure.
Atrial Fibrillation Treatment in T Nagar at Humayun Hospital
At Humayun Hospital, T Nagar, Chennai, our cardiology and internal medicine team provides complete diagnostic and management services for patients with atrial fibrillation and irregular heartbeat.
Our atrial fibrillation treatment in Chennai follows the 2024 ESC AF-CARE framework, with personalised care plans that address each patient's specific AF pattern, stroke risk, symptoms, comorbidities, and treatment preferences.
We offer:
-
12-lead ECG and Holter monitoring for AFib diagnosis and burden assessment in patients with paroxysmal symptoms
-
Echocardiography to assess structural heart disease, left atrial size, and left ventricular function
-
Stroke risk assessment using CHA2-VA scoring with anticoagulation counselling and initiation
-
DOAC prescribing and monitoring with dose-appropriateness review
-
Rate control prescribing, titration, and heart rate monitoring
-
Antiarrhythmic drug therapy initiation and long-term management for rhythm control
-
Cardioversion coordination for eligible patients
-
Referral and coordination for catheter ablation at experienced cardiac electrophysiology centres
-
Comorbidity management including hypertension, diabetes, heart failure, and obesity within the AFib management framework
-
Lifestyle counselling structured around 2024 ESC recommendations on weight, alcohol, exercise, and sleep apnoea
-
Long-term follow-up and periodic reassessment in line with AF-CARE periodic evaluation recommendations
If you or a family member has been told you have an irregular heartbeat, or if you are experiencing palpitations, unexplained breathlessness, or reduced exercise tolerance, early assessment is the most important step you can take.
Chat with our medical assistant for quick guidance and support.




